The acquisition solidifies Neurocrine’s focus on rare neurological disorders, adding a newly-approved, high-potential therapy for Prader-Willi syndrome.
Back
Neurocrine Closes $2.9 Billion Soleno Deal to Add Rare Disease Drug
Neurocrine Biosciences Inc. on Tuesday completed its $2.9 billion all-cash acquisition of Soleno Therapeutics, a deal that adds a first-in-class treatment for the rare genetic disorder Prader-Willi syndrome to its portfolio and expands its footprint in endocrinology.
"Today marks an important advancement in Neurocrine's mission to deliver life-changing treatments for patients with significant unmet needs," Kyle W. Gano, Chief Executive Officer of Neurocrine Biosciences, said in a statement welcoming the Soleno team.
The transaction saw Neurocrine acquire all outstanding shares of Soleno for $53.00 each, a significant investment to secure VYKAT™ XR, a therapy approved by the Food and Drug Administration in March 2025. The deal adds a new revenue stream alongside Neurocrine's blockbuster drug INGREZZA®. Following the announcement, Neurocrine shares traded near their 52-week high of $162.39, reflecting investor confidence.
The acquisition gives Neurocrine control of a recently launched drug targeting an estimated 10,000 patients in the United States with Prader-Willi syndrome, a condition with no other approved treatments for its most severe symptom. For a total equity value of $2.9 billion, Neurocrine is betting that VYKAT XR can become a key growth driver, diversifying its revenue base and cementing its leadership in treating rare neurological and endocrine disorders.
A Strategic Push into Rare Diseases
The addition of VYKAT XR is central to Neurocrine's strategy of building a formidable rare disease franchise. Prader-Willi syndrome (PWS) is a genetic disorder with a defining symptom of hyperphagia—a constant, extreme hunger that can lead to life-threatening complications. VYKAT XR is the first and only approved treatment for this symptom.
This move complements Neurocrine's existing portfolio, which includes INGREZZA for tardive dyskinesia and CRENESSITY for congenital adrenal hyperplasia. The company's Q1 2026 earnings showed strong performance from its current assets, with INGREZZA sales hitting $657 million. The Soleno acquisition is a forward-looking move to sustain growth as the company builds out its pipeline, which includes multiple Phase 3 readouts expected in 2027.
Financial Terms and Market Reaction
The all-cash deal was executed via a tender offer that expired on May 15, with approximately 88.9% of Soleno's shares tendered. The $53.00 per share price represents a substantial investment, reflecting the perceived value of VYKAT XR. The transaction was managed by top-tier financial advisors, with Goldman Sachs & Co. LLC advising Neurocrine and Centerview Partners LLC and Guggenheim Securities, LLC advising Soleno.
The market has reacted positively to Neurocrine's strategic moves, with its stock delivering a 31 percent return over the past year. With a market capitalization of $15.93 billion, the company is using its financial strength to acquire promising assets and deepen its pipeline. The successful completion of the Soleno acquisition is a critical step in this strategy, though the company now faces the task of integrating the new asset and ensuring a successful commercial launch to realize the deal's full value.
This article is for informational purposes only and does not constitute investment advice.
